Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report
DOI:
https://doi.org/10.1080/0284186X.2017.1406668Abstract
No Abstract Available